Cargando…
E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
LESSONS LEARNED. Rate of progression‐free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer. Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a cli...
Autores principales: | Lubner, Sam, Feng, Yang, Mulcahy, Mary, O'Dwyer, Peter, Giang, Guang‐Yu, Hinshaw, J. Louis, Deming, Dustin, Klein, Leonard, Teitelbaum, Ursina, Payne, Jennifer, Engstrom, Paul, Stella, Philip, Meropol, Neal, Benson, Al |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192662/ https://www.ncbi.nlm.nih.gov/pubmed/29853660 http://dx.doi.org/10.1634/theoncologist.2018-0294 |
Ejemplares similares
-
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022) -
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023) -
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016) -
Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up
por: Rosenberg, Ari Joseph, et al.
Publicado: (2019) -
Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)